Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China (mainland).
Med Sci Monit. 2019 Mar 14;25:1917-1927. doi: 10.12659/MSM.914677.
BACKGROUND Numerous studies have been conducted on whether CD28 rs3116496 polymorphism affected cancer susceptibility, and these findings have been controversial. Thus, the purpose of this study was to assess the relationship between rs3116496 and susceptibility to cancer. MATERIAL AND METHODS The research published as of October 25, 2018 were comprehensively searched in PubMed, Embase, Cochrane Library and Chinese Wanfang database, CNKI, CBM. Statistical calculations performed using Stata12.0. RESULTS Overall analyses found that rs3116496 was a risk factor for cancer (C versus T, OR=1.14, 95% CI: 1.01-1.29, PH=0.003), and the heterogeneity was moderate (I²=53.3%). In subgroup analysis results by cancer types, the analysis showed that rs3116496 was a risk factor for breast cancer and leukemia. In the subgroup analysis by ethnicity, rs3116496 was a risk factor for cancer in the Asian population. After PHWE<0.05 was deleted, the analysis showed that rs3116496 might be related to the increased risk of colorectal cancer. CONCLUSIONS Our meta-analysis confirmed that rs3116496 was significantly related to cancer risk, especially in an Asian population, and was strongly correlated with the increased risk of breast cancer, leukemia and colorectal cancer.
许多研究已经探讨了 CD28 rs3116496 多态性是否会影响癌症易感性，但其结果存在争议。因此，本研究旨在评估 rs3116496 与癌症易感性之间的关系。
截至 2018 年 10 月 25 日，全面检索 PubMed、Embase、Cochrane 图书馆和中国万方数据库、中国知网、中国生物医学文献数据库中的相关研究。采用 Stata12.0 进行统计分析。
总体分析发现 rs3116496 是癌症的危险因素（C 与 T 相比，OR=1.14，95%CI：1.01-1.29，PH=0.003），且存在中度异质性（I²=53.3%）。按癌症类型进行亚组分析的结果显示，rs3116496 是乳腺癌和白血病的危险因素。按种族进行亚组分析的结果显示，rs3116496 是亚洲人群癌症的危险因素。删除 PHWE<0.05 后，分析显示 rs3116496 可能与结直肠癌风险增加有关。
本荟萃分析证实 rs3116496 与癌症风险显著相关，尤其是在亚洲人群中，且与乳腺癌、白血病和结直肠癌风险增加密切相关。
